Amgen (AMGN) 10-Q 1 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 24, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Amgen Inc.
Entity Central Index Key	0000318154
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		609,935,682

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 1,992	$ 2,311
Other comprehensive income (loss), net of reclassification adjustments and taxes:
(Losses) gains on foreign currency translation	(13)	29
Gains on cash flow hedges	45	6
Gains (losses) on available-for-sale securities	221	(343)
Other	0	2
Other comprehensive income (loss), net of taxes	253	(306)
Comprehensive income	$ 2,245	$ 2,005

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Total revenues	$ 5,557	$ 5,554
Operating expenses:
Cost of sales	1,055	944
Research and development	879	760
Selling, general and administrative	1,154	1,127
Other	(3)	(3)
Total operating expenses	3,085	2,828
Operating income	2,472	2,726
Interest expense, net	343	338
Interest and other income, net	185	231
Income before income taxes	2,314	2,619
Provision for income taxes	322	308
Net income	$ 1,992	$ 2,311
Earnings per share:
Basic (in usd per share)	$ 3.20	$ 3.27
Diluted (in usd per share)	$ 3.18	$ 3.25
Shares used in calculation of earnings per share:
Basic (in shares)	622	707
Diluted (in shares)	626	711
Product sales [Member]
Revenues:
Product sales	$ 5,286	$ 5,343
Other revenues [Member]
Revenues:
Total revenues	$ 271	$ 211

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 7,358	$ 6,945
Marketable securities	18,943	22,359
Trade receivables, net	3,771	3,580
Inventories	3,016	2,940
Other current assets	2,063	1,794
Total current assets	35,151	37,618
Property, plant and equipment, net	4,892	4,958
Intangible assets, net	7,124	7,443
Goodwill	14,692	14,699
Other assets	2,138	1,698
Total assets	63,997	66,416
Current liabilities:
Accounts payable	1,091	1,207
Accrued liabilities	7,910	7,862
Current portion of long-term debt	3,705	4,419
Total current liabilities	12,706	13,488
Long-term debt	29,319	29,510
Long-term deferred tax liabilities	811	864
Long-term tax liabilities	8,869	8,770
Other noncurrent liabilities	1,460	1,284
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 614.4 shares in 2019 and 629.6 shares in 2018	31,243	31,246
Accumulated deficit	(19,895)	(17,977)
Accumulated other comprehensive loss	(516)	(769)
Total stockholders’ equity	10,832	12,500
Total liabilities and stockholders’ equity	$ 63,997	$ 66,416

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized	2,750	2,750
Common stock and additional paid-in capital, shares outstanding	614.4	629.6

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Number of shares of common stock [Member]	Common stock and additional paid-in capital [Member]	Accumulated deficit [Member]	Accumulated other comprehensive loss [Member]
Beginning Balance, Shares at Dec. 31, 2017		722.2
Balance as of beginning of period at Dec. 31, 2017	$ 25,241		$ 30,992	$ (5,072)	$ (679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	2,311			2,311
Other comprehensive income (loss), net of taxes	(306)				(306)
Dividends declared on common stock	(877)			(877)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.6
Issuance of common stock in connection with the Company’s equity award programs	5		5
Stock-based compensation expense	61		61
Tax impact related to employee stock-based compensation expense	(57)		(57)
Repurchases of common stock, Shares		(56.4)
Repurchases of common stock	(10,787)			(10,787)
Ending Balance, Shares at Mar. 31, 2018		666.4
Balance as of end of period at Mar. 31, 2018	$ 15,620		31,001	(14,387)	(994)
Beginning Balance, Shares at Dec. 31, 2018	629.6	629.6
Balance as of beginning of period at Dec. 31, 2018	$ 12,500		31,246	(17,977)	(769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	1,992			1,992
Other comprehensive income (loss), net of taxes	253				253
Dividends declared on common stock	(879)			(879)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.7
Issuance of common stock in connection with the Company’s equity award programs	6		6
Stock-based compensation expense	64		64
Tax impact related to employee stock-based compensation expense	(73)		(73)
Repurchases of common stock, Shares		(15.9)
Repurchases of common stock	$ (3,031)			(3,031)
Ending Balance, Shares at Mar. 31, 2019	614.4	614.4
Balance as of end of period at Mar. 31, 2019	$ 10,832		$ 31,243	$ (19,895)	$ (516)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	1 Months Ended		3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]
Common stock, dividends declared per share (in usd per share)	$ 1.45	$ 1.45	$ 1.45	$ 1.32

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income	$ 1,992	$ 2,311
Depreciation, amortization and other	495	471
Deferred income taxes	(50)	(72)
Other items, net	24	98
Changes in operating assets and liabilities, net of acquisition:
Trade receivables, net	(207)	(384)
Inventories	(28)	(107)
Other assets	(249)	(135)
Accounts payable	(112)	(278)
Accrued income taxes, net	277	353
Long-term tax liabilities	100	63
Other liabilities	(397)	407
Net cash provided by operating activities	1,845	2,727
Cash flows from investing activities:
Purchases of marketable securities	(6,898)	(2,732)
Proceeds from sales of marketable securities	125	16,694
Proceeds from maturities of marketable securities	10,455	900
Cash acquired in acquisition, net of cash paid	0	197
Purchases of property, plant and equipment	(116)	(155)
Other	(11)	2
Net cash provided by investing activities	3,555	14,906
Cash flows from financing activities:
Repayment of debt	(1,000)	0
Repurchases of common stock	(3,032)	(10,697)
Dividends paid	(901)	(951)
Other	(54)	(44)
Net cash used in financing activities	(4,987)	(11,692)
Increase in cash and cash equivalents	413	5,941
Cash and cash equivalents at beginning of period	6,945	3,800
Cash and cash equivalents at end of period	$ 7,358	$ 9,741

Summary of significant accounti

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Basis of presentation The financial information for the three months ended March 31, 2019 and 2018 , is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2018 . Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $7.9 billion and $7.8 billion as of March 31, 2019 and December 31, 2018 , respectively. Leases Adoption of new lease standard In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method. This approach provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is related primarily to previously existing lease liabilities. The standard did not materially impact our Condensed Consolidated Statements of Income and had no impact on our Condensed Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 8, Leases. Lease recognition At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Condensed Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate. Other recent accounting pronouncements In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.

Revenues

Revenues	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenues	Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe. Revenues were as follows (in millions): Three months ended March 31, 2019 2018 US ROW Total US ROW Total Enbrel ® (etanercept) $ 1,106 $ 45 $ 1,151 $ 1,050 $ 55 $ 1,105 Neulasta ® (pegfilgrastim) 893 128 1,021 1,009 146 1,155 Prolia ® (denosumab) 390 202 592 320 174 494 XGEVA ® (denosumab) 356 115 471 332 113 445 Aranesp ® (darbepoetin alfa) 182 232 414 225 229 454 KYPROLIS ® (carfilzomib) 154 91 245 137 85 222 EPOGEN ® (epoetin alfa) 219 — 219 244 — 244 Sensipar ® /Mimpara ® (cinacalcet) 135 78 213 409 88 497 Other products 556 404 960 421 306 727 Total product sales (1) $ 3,991 $ 1,295 5,286 $ 4,147 $ 1,196 5,343 Other revenues 271 211 Total revenues $ 5,557 $ 5,554 ____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2019 and 2018 .

Income taxes

Income taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The effective tax rates for the three months ended March 31, 2019 and 2018, were 13.9% and 11.8% , respectively. The increase in our effective tax rate for the three months ended March 31, 2019 , was due primarily to a prior-year tax benefit associated with intercompany sales under U.S. corporate tax reform. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes and that is subject to tax incentive grants through 2035; these earnings are subject to U.S. tax at a reduced 10.5% rate. The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by the tax authorities in those jurisdictions. Significant disputes may arise with authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and the interpretation of the relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculation but continued to propose substantial adjustments. We disagree with the proposed adjustments and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we deem necessary, we will vigorously contest the proposed adjustments through the judicial process. Final resolution of this complex matter is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. In addition, we are currently under examination by a number of other state and foreign tax jurisdictions. During the three months ended March 31, 2019 , the gross amounts of our unrecognized tax benefits (UTBs) increased $90 million as a result of tax positions taken during the current year. Substantially all of the UTBs as of March 31, 2019 , if recognized, would affect our effective tax rate.

Earnings per share

Earnings per share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Earnings per share	Earnings per share The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method. The computations for basic and diluted EPS were as follows (in millions, except per-share data): Three months ended 2019 2018 Income (Numerator): Net income for basic and diluted EPS $ 1,992 $ 2,311 Shares (Denominator): Weighted-average shares for basic EPS 622 707 Effect of dilutive securities 4 4 Weighted-average shares for diluted EPS 626 711 Basic EPS $ 3.20 $ 3.27 Diluted EPS $ 3.18 $ 3.25 For the three months ended March 31, 2019 and 2018 , the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Investments

Investments	3 Months Ended
	Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of March 31, 2019 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,709 $ — $ (27 ) $ 2,682 U.S. Treasury bills 3,475 — — 3,475 Other government-related debt securities: U.S. 112 — (1 ) 111 Foreign and other 964 4 (10 ) 958 Corporate debt securities: Financial 2,771 1 (22 ) 2,750 Industrial 2,481 4 (27 ) 2,458 Other 572 1 (7 ) 566 Residential-mortgage-backed securities 1,404 — (22 ) 1,382 Other mortgage- and asset-backed securities 478 — (11 ) 467 Money market mutual funds 4,375 — — 4,375 Other short-term interest-bearing securities 6,428 — — 6,428 Total interest-bearing securities $ 25,769 $ 10 $ (127 ) $ 25,652 Types of securities as of December 31, 2018 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,710 $ — $ (47 ) $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. 112 — (2 ) 110 Foreign and other 972 1 (41 ) 932 Corporate debt securities: Financial 2,778 — (81 ) 2,697 Industrial 2,603 — (99 ) 2,504 Other 583 — (21 ) 562 Residential-mortgage-backed securities 1,458 — (36 ) 1,422 Other mortgage- and asset-backed securities 483 — (14 ) 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities 3,515 — — 3,515 Total interest-bearing securities $ 29,064 $ 1 $ (341 ) $ 28,724 The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): Condensed Consolidated Balance Sheets locations March 31, December 31, Cash and cash equivalents $ 6,709 $ 6,365 Marketable securities 18,943 22,359 Total interest-bearing securities $ 25,652 $ 28,724 Cash and cash equivalents in the above table excludes bank account cash of $649 million and $580 million as of March 31, 2019 and December 31, 2018 , respectively. The fair values of interest-bearing securities by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions): Contractual maturities March 31, December 31, Maturing in one year or less $ 14,357 $ 17,424 Maturing after one year through three years 4,600 3,356 Maturing after three years through five years 3,987 5,168 Maturing after five years through ten years 859 885 Mortgage- and asset-backed securities 1,849 1,891 Total interest-bearing securities $ 25,652 $ 28,724 For the three months ended March 31, 2019 and 2018 , realized gains on interest-bearing securities were $1 million and $17 million , respectively, and realized losses on interest-bearing securities were $5 million and $151 million , respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method. The fair values and gross unrealized losses of interest-bearing securities in an unrealized loss position aggregated by type and length of time that the securities have been in a continuous loss position were as follows (in millions): Less than 12 months 12 months or more Types of securities as of March 31, 2019 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,190 $ (11 ) $ 1,452 $ (16 ) Other government-related debt securities: U.S. — — 111 (1 ) Foreign and other 410 (6 ) 307 (4 ) Corporate debt securities: Financial 1,783 (14 ) 822 (8 ) Industrial 1,516 (20 ) 634 (7 ) Other 454 (6 ) 36 (1 ) Residential-mortgage-backed securities 558 (9 ) 809 (13 ) Other mortgage- and asset-backed securities 17 — 450 (11 ) Total $ 5,928 $ (66 ) $ 4,621 $ (61 ) Less than 12 months 12 months or more Types of securities as of December 31, 2018 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,219 $ (21 ) $ 1,444 $ (26 ) Other government-related debt securities: U.S. — — 110 (2 ) Foreign and other 631 (31 ) 240 (10 ) Corporate debt securities: Financial 1,968 (59 ) 718 (22 ) Industrial 1,898 (81 ) 529 (18 ) Other 529 (20 ) 28 (1 ) Residential-mortgage-backed securities 576 (14 ) 840 (22 ) Other mortgage- and asset-backed securities 17 — 451 (14 ) Total $ 6,838 $ (226 ) $ 4,360 $ (115 ) The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security. As of March 31, 2019 , unrealized losses on available-for-sale investments were due primarily to higher interest rates than at the time the securities were purchased. As of March 31, 2019 and December 31, 2018 , we believe the cost bases for our available-for-sale investments were recoverable in all material respects. Equity securities We held investments in equity securities with readily determinable fair values of $246 million and $176 million as of March 31, 2019 and December 31, 2018 , respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on equity securities with readily determinable fair values, including gains and losses recognized on sales, were not material for the three months ended March 31, 2019 and 2018. As of March 31, 2019 and December 31, 2018, respectively, we held investments of $185 million and $222 million in equity securities without readily determinable fair values, which are included in Other assets in the Condensed Consolidated Balance Sheets. Adjustments to the carrying values of these securities were not material for the three months ended March 31, 2019 and 2018. Limited partnership investments We held limited partnership investments of $275 million and $285 million as of March 31, 2019 and December 31, 2018 , respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments are measured by using the net asset values of the underlying investments as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of March 31, 2019 , unfunded additional commitments to be made during the next several years for these investments were not material. Gains and losses recognized on our limited partnership investments were not material for the three months ended March 31, 2019 and 2018.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in millions): March 31, December 31, Raw materials $ 276 $ 257 Work in process 1,770 1,660 Finished goods 970 1,023 Total inventories $ 3,016 $ 2,940

Goodwill and other intangible a

Goodwill and other intangible assets	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Goodwill The change in the carrying amount of goodwill was as follows (in millions): Three months ended Beginning balance $ 14,699 Currency translation adjustment (7 ) Ending balance $ 14,692 Other intangible assets Other intangible assets consisted of the following (in millions): March 31, 2019 December 31, 2018 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Finite-lived intangible assets: Developed-product-technology rights $ 12,559 $ (7,639 ) $ 4,920 $ 12,573 $ (7,479 ) $ 5,094 Licensing rights 3,693 (2,064 ) 1,629 3,772 (2,032 ) 1,740 Marketing-related rights 1,211 (947 ) 264 1,297 (1,019 ) 278 Research and development technology rights 1,145 (889 ) 256 1,148 (872 ) 276 Total finite-lived intangible assets 18,608 (11,539 ) 7,069 18,790 (11,402 ) 7,388 Indefinite-lived intangible assets: In-process research and development 55 — 55 55 — 55 Total other intangible assets $ 18,663 $ (11,539 ) $ 7,124 $ 18,845 $ (11,402 ) $ 7,443 Developed-product-technology rights consist of rights related to marketed products acquired in business combinations. Licensing rights consist primarily of contractual rights acquired in business combinations to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights consist primarily of rights related to the sale and distribution of marketed products. Research and development (R&D) technology rights pertain to technology used in R&D that have alternative future uses. In-process research and development (IPR&D) consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the three months ended March 31, 2019 and 2018 , we recognized amortization associated with our finite-lived intangible assets, included primarily in Cost of sales in the Condensed Consolidated Statements of Income, of $315 million and $320 million , respectively. The total estimated amortization for our finite-lived intangible assets for the remaining nine months ending December 31, 2019, and the years ending December 31, 2020 , 2021 , 2022 , 2023 and 2024 , are $1.0 billion , $1.2 billion , $1.0 billion , $0.9 billion , $0.9 billion and $0.8 billion , respectively.

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	Leases On January 1, 2019, we adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. Certain required disclosures have been made on a prospective basis in accordance with the guidance of the standard. See Note 1, Summary of significant accounting policies. We lease certain facilities and equipment related primarily to administrative, R&D and sales and marketing activities. Leases with lease terms of 12 months or less are expensed on a straight-line basis over the lease term and are not recorded in the Condensed Consolidated Balance Sheets. Most leases include one or more options to renew, with renewal terms that can extend the lease term up to seven years . The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain any residual value guarantees nor impose any significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&D and administrative space. The following table summarizes information related to our leases, which are all classified as operating, included in our Condensed Consolidated Balance Sheets (in millions): Condensed Consolidated Balance Sheets locations March 31, 2019 Assets: Other assets $ 417 Liabilities: Accrued liabilities $ 120 Other noncurrent liabilities 368 Total lease liabilities $ 488 The components of net lease costs were as follows (in millions): Lease costs Three months ended March 31, 2019 Operating (1) $ 48 Sublease income (8 ) Total net lease costs $ 40 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the three months ended March 31, 2019. Maturities of lease liabilities as of March 31, 2019, were as follows (in millions): Maturity dates Operating leases Remaining nine months ending December 31, 2019 $ 135 2020 133 2021 107 2022 63 2023 48 Thereafter 41 Total lease payments (1) 527 Less imputed interest (39 ) Present value of lease liabilities $ 488 ____________ (1) Includes future rental commitments for abandoned leases of $204 million . We expect to receive total future rental income of $166 million related to noncancelable subleases for abandoned facilities. The weighted-average remaining lease term and weighted-average discount rate of our leases were 4.5 years and 3.32% , respectively, as of March 31, 2019. Cash and noncash information related to our leases was as follows (in millions): Three months ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 34 ROU assets obtained in exchange for lease obligations: Operating leases $ 8

Financing arrangements

Financing arrangements	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Financing arrangements	Financing arrangements Our borrowings consisted of the following (in millions): March 31, December 31, 5.70% notes due 2019 (5.70% 2019 Notes) $ — $ 1,000 1.90% notes due 2019 (1.90% 2019 Notes) 700 700 Floating Rate Notes due 2019 550 550 2.20% notes due 2019 (2.20% 2019 Notes) 1,400 1,400 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) 757 774 4.50% notes due 2020 (4.50% 2020 Notes) 300 300 2.125% notes due 2020 (2.125% 2020 Notes) 750 750 Floating Rate Notes due 2020 300 300 2.20% notes due 2020 (2.20% 2020 Notes) 700 700 3.45% notes due 2020 (3.45% 2020 Notes) 900 900 4.10% notes due 2021 (4.10% 2021 Notes) 1,000 1,000 1.85% notes due 2021 (1.85% 2021 Notes) 750 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,750 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,402 1,433 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 703 713 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 841 860 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 619 606 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 912 893 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (886 ) (896 ) Fair value adjustments 77 (53 ) Total carrying value of debt 33,024 33,929 Less current portion (3,705 ) (4,419 ) Total long-term debt $ 29,319 $ 29,510 There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6% , respectively.

Stockholders' equity

Stockholders' equity	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Stock repurchase program Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): 2019 2018 Shares Dollars Shares Dollars First quarter 15.9 $ 3,031 56.4 $ 10,787 As of March 31, 2019 , $2.1 billion of authority remained available under our stock repurchase program. Dividends In March 2019, the Board of Directors declared a quarterly cash dividend of $1.45 per share, which will be paid in June 2019. In December 2018, the Board of Directors declared a quarterly cash dividend of $1.45 per share, which was paid in March 2019. Accumulated other comprehensive income (loss) The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions): Foreign currency translation Cash flow hedges Available-for-sale securities Other AOCI Balance as of December 31, 2018 $ (670 ) $ 241 $ (338 ) $ (2 ) $ (769 ) Foreign currency translation adjustments (13 ) — — — (13 ) Unrealized gains — 30 218 — 248 Reclassification adjustments to income — 28 4 — 32 Income taxes — (13 ) (1 ) — (14 ) Balance as of March 31, 2019 $ (683 ) $ 286 $ (117 ) $ (2 ) $ (516 ) Reclassifications out of AOCI and into earnings were as follows (in millions): Three months ended March 31, Components of AOCI 2019 2018 Condensed Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains (losses) $ 14 $ (34 ) Product sales Cross-currency swap contract (losses) gains (42 ) 164 Interest and other income, net (28 ) 130 Income before income taxes 6 (28 ) Provision for income taxes $ (22 ) $ 102 Net income Available-for-sale securities: Net realized losses $ (4 ) $ (134 ) Interest and other income, net — 1 Provision for income taxes $ (4 ) $ (133 ) Net income

Fair value measurement

Fair value measurement	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 — Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Quoted prices in Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of March 31, 2019, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 2,682 $ — $ — $ 2,682 U.S. Treasury bills 3,475 — — 3,475 Other government-related debt securities: U.S. — 111 — 111 Foreign and other — 958 — 958 Corporate debt securities: Financial — 2,750 — 2,750 Industrial — 2,458 — 2,458 Other — 566 — 566 Residential-mortgage-backed securities — 1,382 — 1,382 Other mortgage- and asset-backed securities — 467 — 467 Money market mutual funds 4,375 — — 4,375 Other short-term interest-bearing securities — 6,428 — 6,428 Equity securities 246 — — 246 Derivatives: Foreign currency contracts — 238 — 238 Cross-currency swap contracts — 143 — 143 Interest rate swap contracts — 94 — 94 Total assets $ 10,778 $ 15,595 $ — $ 26,373 Liabilities: Derivatives: Foreign currency contracts $ — $ 8 $ — $ 8 Cross-currency swap contracts — 429 — 429 Interest rate swap contracts — 54 — 54 Contingent consideration obligations — — 66 66 Total liabilities $ — $ 491 $ 66 $ 557 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of December 31, 2018, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 2,663 $ — $ — $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. — 110 — 110 Foreign and other — 932 — 932 Corporate debt securities: Financial — 2,697 — 2,697 Industrial — 2,504 — 2,504 Other — 562 — 562 Residential-mortgage-backed securities — 1,422 — 1,422 Other mortgage- and asset-backed securities — 469 — 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities — 3,515 — 3,515 Equity securities 176 — — 176 Derivatives: Foreign currency contracts — 182 — 182 Cross-currency swap contracts — 170 — 170 Interest rate swap contracts — 56 — 56 Total assets $ 16,689 $ 12,619 $ — $ 29,308 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 401 — 401 Interest rate swap contracts — 149 — 149 Contingent consideration obligations — — 72 72 Total liabilities $ — $ 576 $ 72 $ 648 Interest-bearing and equity securities The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment. Most of our other government-related and corporate debt securities are investment grade and have maturity dates of five years or less from the balance sheet date. Our other government-related debt securities portfolio is composed of securities with weighted-average credit ratings of A– or equivalent by Standard & Poor’s Financial Services LLC (S&P), Moody’s Investors Service, Inc. (Moody’s), or Fitch Ratings, Inc. (Fitch); and our corporate debt securities portfolio has weighted-average credit ratings of A– or equivalent by Fitch and BBB + or equivalent by S&P or Moody’s. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. Our residential-mortgage-, other-mortgage- and asset-backed-securities portfolio is composed entirely of senior tranches with credit ratings of AAA by S&P, Moody’s or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs. We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates. Derivatives All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, the London Interbank Offered Rate (LIBOR), swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments. Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments. Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments. Contingent consideration obligations As a result of our business acquisitions, we have incurred contingent consideration obligations. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. These inputs include, as applicable, estimated probabilities and the timing of achieving specified regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income. Changes in the carrying amounts of contingent consideration obligations for the three months ended March 31, 2019 and 2018 were not material. During the three months ended March 31, 2019 and 2018 , there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis. Summary of the fair values of other financial instruments Cash equivalents The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. Borrowings We estimated the fair values of our borrowings by using Level 2 inputs. As of March 31, 2019 and December 31, 2018 , the aggregate fair values of our borrowings were $34.8 billion and $35.0 billion , respectively, and the carrying values were $33.0 billion and $33.9 billion , respectively.

Derivative instruments

Derivative instruments	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	Derivative instruments The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes. Cash flow hedges We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon , with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of both March 31, 2019 and December 31, 2018 , we had outstanding foreign currency forward contracts with aggregate notional amounts of $4.5 billion and outstanding foreign currency option contracts with aggregate notional amounts of $21 million . We have designated these foreign currency forward and foreign currency option contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings. To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps as of March 31, 2019 , were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 2.125% 2019 euro Notes € 675 2.1 % $ 864 2.6 % 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 % In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i n the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the three months ended March 31, 2019 , and amounts expected to be recognized during the subsequent 12 months are not material. The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Derivatives in cash flow hedging relationships 2019 2018 Foreign currency contracts $ 85 $ (89 ) Cross-currency swap contracts (55 ) 238 Total unrealized gains $ 30 $ 149 The locations in the Condensed Consolidated Statements of Income and the gains and losses reclassified out of AOCI and into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Derivatives in cash flow hedging relationships Condensed Consolidated Statements of Income locations 2019 2018 Foreign currency contracts Product sales $ 14 $ (34 ) Cross-currency swap contracts Interest and other income, net (42 ) 164 Total realized (losses) gains $ (28 ) $ 130 No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of March 31, 2019 , we expected to reclassify $83 million of net losses on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. Fair value hedges To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of March 31, 2019 and December 31, 2018 , we had interest rate swap contracts with aggregate notional amounts of $10.95 billion that hedge certain of our long-term debt issuances. For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt. Net unrealized gains and losses on our outstanding interest rate swap contracts were as follows (in millions): Three months ended Derivatives in fair value hedging relationships 2019 2018 Net unrealized gains (losses) recognized on interest rate swap contracts $ 133 $ (164 ) Net unrealized (losses) gains recognized on related hedged debt $ (133 ) $ 164 The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) Condensed Consolidated Balance Sheets locations March 31, 2019 December 31, 2018 March 31, 2019 December 31, 2018 Current portion of long-term debt $ 1,398 $ 2,396 $ (2 ) $ (3 ) Long-term debt $ 9,494 $ 9,361 $ 79 $ (50 ) ____________ (1) Current portion of long-term debt includes $1.0 billion of carrying value with discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $137 million of carrying value with discontinued hedging relationships as of March 31, 2019 and December 31, 2018 . (2) Current portion of long-term debt includes $3 million of hedging adjustments on discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $37 million of hedging adjustments on discontinued hedging relationships as of March 31, 2019 and December 31, 2018 . The following table summarizes the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,286 $ 185 $ (343 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 14 $ — $ — Cross-currency swap contracts $ — $ (42 ) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (130 ) Derivatives designated as hedging instruments $ — $ — $ 133 __________ (1) The amounts include benefits of $3 million related to the amortization of the cumulative amount of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships for the three months ended March 31, 2019 . Derivatives not designated as hedges To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. These exposures are hedged on a month-to-month basis. As of March 31, 2019 and December 31, 2018 , the total notional amounts of these foreign currency forward contracts were $891 million and $737 million , respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three months ended March 31, 2019 and 2018. The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities March 31, 2019 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 238 Accrued liabilities/ Other noncurrent liabilities $ 8 Cross-currency swap contracts Other current assets/ Other assets 143 Accrued liabilities/ Other noncurrent liabilities 429 Interest rate swap contracts Other current assets/ Other assets 94 Accrued liabilities/ Other noncurrent liabilities 54 Total derivatives designated as hedging instruments 475 491 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets — Accrued liabilities — Total derivatives not designated as hedging instruments — — Total derivatives $ 475 $ 491 Derivative assets Derivative liabilities December 31, 2018 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 181 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 170 Accrued liabilities/ Other noncurrent liabilities 401 Interest rate swap contracts Other current assets/ Other assets 56 Accrued liabilities/ Other noncurrent liabilities 149 Total derivatives designated as hedging instruments 407 576 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 408 $ 576 Our derivative contracts that were in liability positions as of March 31, 2019 , contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur. The cash flow effects of our derivative contracts are included in Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows.

Contingencies and commitments

Contingencies and commitments	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2018 , Part I, Item 1A. Risk Factors— Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing or in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing or in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Novartis Breach of Contract Action On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York against Novartis Pharma AG (Novartis) seeking a declaratory judgment that Novartis materially breached two collaboration agreements related to the development and commercialization of Aimovig ® (erenumab-aooe) due to Novartis’ affiliate Sandoz Gmbh (Sandoz) entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig ® and entrant in the calcitonin gene-related peptide (CGRP)-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis’ complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Sensipar ® (cinacalcet) Litigation Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) ANDA Patent Litigation On March 19, 2019, Amgen filed an emergency motion for an injunction pending appeal, seeking an order from the U.S. District Court for the District of Delaware (the Delaware District Court) enjoining defendant Piramal Healthcare UK Limited (Piramal) from making, using, selling, offering for sale or importing its generic cinacalcet product. Amgen’s motion follows an announcement that Slate Run Pharmaceuticals LLC (Slate Run), in partnership with Piramal, had begun selling Piramal’s generic cinacalcet product at risk notwithstanding the appeals pending at the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On April 15, 2019, the Delaware District Court signed an order enjoining Piramal and Slate Run from selling their generic cinacalcet product until certain events occur related to a decision by the Federal Circuit Court on the parties’ appeal. The order has no effect on the product that Piramal and Slate Run have already sold to third parties. On March 21, 2019, defendants Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, Sun) filed a motion to enforce the settlement agreement entered between Amgen and Sun, contending that Sun’s generic cinacalcet product should not be held off the U.S. market. On March 26, 2019, the Delaware District Court denied the joint motion for indicative ruling of Watson Laboratories, Inc. and Actavis Pharma, Inc. (collectively, Watson) and Amgen, which had asked the court to vacate its final judgment of noninfringement as to Watson and to enter a proposed consent judgment of infringement and validity of Amgen’s U.S. Patent No. 9,375,405 and an injunction prohibiting the making, having made, using, selling, offering to sell or distributing Watson’s generic cinacalcet product in the United States, or importing Watson’s generic cinacalcet product into the United States, consistent with a confidential settlement agreement entered into by the parties. On April 10, 2019, Amgen filed an appeal to the Federal Circuit Court. On April 29, 2019, the Federal Circuit Court lifted the stay of Amgen’s appeal of the judgment of noninfringement as to Watson and consolidated it with Amgen’s appeal of the Delaware District Court’s denial of the joint motion for indicative ruling. Cipla Ltd. v. Amgen Inc. On March 11, 2019, following an announcement by Cipla Limited and Cipla USA, Inc. (collectively, Cipla) that it had begun selling its generic cinacalcet product in the United States, Amgen filed in the Delaware District Court a counterclaim and related motion for preliminary injunction in Cipla’s lawsuit seeking a declaration that provisions of its February 2018 settlement agreement with Amgen have been triggered by the at-risk launch of a generic cinacalcet product by Teva Pharmaceutical Industries Ltd. (Teva), an affiliate of Watson. Amgen’s motion seeks to prohibit Cipla from making, having made, using, selling, offering to sell or distributing its generic cinacalcet product in breach of such settlement agreement. On April 2, 2019, the Delaware District Court held a hearing on Amgen’s motion for preliminary injunction. Sensipar ® Antitrust Class Actions From February 21, 2019, to April 10, 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. Two of those actions were brought in the Delaware District Court, captioned UFCW Local 1500 Welfare Fund v. Amgen Inc., et al. (February 21, 2019) (Local 1500) and Cesar Castillo, Inc. v. Amgen Inc., et al. (February 26, 2019) (Castillo). The third action was brought in the U.S. District Court for the District of New Jersey (the New Jersey District Court), captioned Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al. (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar ® and alleges that the plaintiffs have overpaid for Sensipar ® as a result of Amgen’s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson and Teva of the parties’ patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys’ fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with Cipla Ltd. v. Amgen Inc. , consolidated and designated as a MDL in the Delaware District Court. Sanofi / Regeneron Repatha ® (evolocumab) Patent Litigation On February 25, 2019, a jury of the Delaware District Court unanimously upheld the validity of claims 7 and 15 of U.S. Patent No. 8,829,165 (the ’165 Patent) and claim 7 of U.S. Patent No. 8,859,741 (the ’741 Patent) in our infringement action against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron). The jury also found that claims 19 and 29 of the ’165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse judgment as a matter of law or for a new trial with respect to claims 7 and 15 of the ’165 Patent and claim 7 of the ’741 Patent, and Amgen filed a motion for a permanent injunction. The Delaware District Court has scheduled hearing dates on Amgen’s motion for a permanent injunction for June 6, 13 and 21, 2019. KYPROLIS ® (carfilzomib) ANDA Patent Litigation On March 4, 2019, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics, Inc. and Breckenridge Pharmaceutical, Inc. (Breckenridge), providing that Breckenridge infringes the asserted claims of U.S. Patent Nos. 7,417,042; 7,737,112 and 8,207,125, and consolidated this lawsuit against Breckenridge into the existing consolidated case, Onyx Therapeutics, Inc. v. Cipla Limited, et al. , for all purposes. Trial in the consolidated case is scheduled to commence on May 6, 2019. Bioepis ENBREL (etanercept) Patent Litigation On April 30, 2019, Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis’s submission of an application for U.S. Food and Drug Administration (FDA) licensure of an etanercept product as biosimilar to Amgen’s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182 (the ’182 Patent); 8,163,522 (the ’522 Patent); 7,915,225 (the ’225 Patent); 8,119,605 (the ’605 Patent); and 8,722,631 (the ’631 Patent). By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. NEUPOGEN ® (filgrastim) / Neulasta ® (pegfilgrastim) Patent Litigation Apotex NEUPOGEN ® / Neulasta ® Patent Litigation On April 5, 2019, the U.S. District Court for the Southern District of Florida (the Florida District Court) denied the motion of Apotex Inc. and Apotex Corporation (collectively, Apotex) to dismiss Amgen’s complaint for failure to state a claim. On April 18, 2019, Apotex answered the complaint including counterclaims seeking declaratory judgments of noninfringement and invalidity. Coherus Neulasta ® Patent Litigation A hearing on Amgen’s Federal Circuit Court appeal of the final judgment dismissing Amgen’s lawsuit against Coherus BioSciences, Inc. (Coherus) for infringement of Amgen’s U.S. Patent No. 8,273,707 is scheduled for May 8, 2019. As previously disclosed, we are also engaged in a separate lawsuit in the Ventura County Superior Court in which we have alleged that Coherus and others misappropriated our confidential information and trade secrets through the hiring of former Amgen employees and that the defendants have used such information to develop and market UDENYCA TM , as biosimilar to Amgen’s Neulasta ® . On March 27, 2019, the Ventura County Superior Court ordered Howard Weiser dismissed from the lawsuit based on a joint request regarding settlement filed on behalf of Amgen and Mr. Weiser. Trial in the misappropriation and trade secret litigation began on April 22, 2019. Pfizer NEUPOGEN ® Patent Litigation On March 22, 2019, Amgen filed an amended complaint against Pfizer Inc. and Hospira Inc. (collectively, Pfizer) in the Delaware District Court narrowing the patent claims at issue in the infringement dispute and adding a request for damages. On April 11, 2019, Pfizer answered Amgen’s amended complaint including counterclaims seeking declaratory judgments of noninfringement and invalidity. Sandoz NEUPOGEN ® / Neulasta ® Patent Litigation On February 21, 2019, Sandoz Inc. (Sandoz) filed a new lawsuit in the U.S. District Court for the Northern District of California (the California Northern District Court) against Amgen Inc. and Amgen Manufacturing, Limited seeking a judgment of noninfringement and invalidity of the ’997 Patent. The lawsuit stems from Sandoz filing applications under the Biologics Price Competition and Innovation Act for the FDA licensure of filgrastim and pegfilgrastim products as biosimilar to NEUPOGEN ® and Neulasta ® , respectively. On April 24, 2019, Amgen filed a motion to dismiss the lawsuit for failure to state a claim. Patent Trial and Appeal Board Patent Challenges On March 7, 2019, Kashiv Biosciences, LLC, formerly known as Adello Biologics, LLC (Kashiv), filed petitions seeking to institute inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) to challenge the patentability of each claim of U.S. Patent Nos. 8,940,878 (the ’878 Patent) and 9,643,997 (the ’997 Patent). The ’878 Patent is also among the patents at issue in the previously-disclosed litigation between Amgen Inc. and Amgen Manufacturing, Limited (collectively, Amgen) and Kashiv, Amneal Pharmaceuticals LLC, and Amneal Pharmaceuticals, Inc. (the Kashiv NEUPOGEN ® litigation) and in the previously-disclosed litigations between Amgen and Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (the Sandoz NEUPOGEN ® litigation) and between Amgen and Sandoz Inc., Sandoz International GmbH, Sandoz GmbH and Lek Pharmaceuticals d.d. (the Sandoz Neulasta ® litigation). The ’997 Patent is also among the patents at issue in the Kashiv NEUPOGEN ® litigation, the Pfizer NEUPOGEN ® Patent Litigation, the new Sandoz NEUPOGEN ® / Neulasta ® Patent Litigation and the previously-disclosed litigation between Amgen and Mylan Inc., Mylan Pharmaceuticals Inc., Mylan GmbH, and Mylan N.V. The deadline for Amgen to file a preliminary response to these IPR petitions is June 14, 2019, after which the PTAB will have three months to render a decision regarding whether to institute PTAB trial proceedings on the ’878 and ’997 Patents. In a separate challenge, on April 14, 2019, Fresenius Kabi USA, LLC and Fresenius Kabi SwissBiosim GmbH filed a petition seeking to institute IPR proceedings before the PTAB to challenge the patentability of U.S. Patent No. 9,856,287 (the ’287 Patent). The ’287 Patent is also the subject of the Apotex NEUPOGEN ® / Neulasta ® Patent Litigation and is among the patents at issue in the Kashiv NEUPOGEN ® litigation. The patent owner preliminary response to the IPR petition is due July 17, 2019, after which the PTAB will have three months to render a decision regarding whether to institute PTAB trial proceedings on the ’287 Patent. In a separate challenge, on April 19, 2019, the PTAB granted Apotex and Kashiv’s previously-disclosed petition to institute post grant review proceedings on the ’287 Patent, challenging claims of the ’287 Patent as unpatentable. Amgen’s response to the petition is due July 11, 2019. AMJEVITA TM (adalimumab-atto) / AMGEVITA TM Patent Litigation On April 18, 2019, Amgen responded to the lawsuit filed by Coherus, denying patent infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed by Amgen. MVASI TM (bevacizumab-awwb) Patent Litigation On March 29, 2019, Genentech, Inc. (Genentech) and City of Hope filed a third lawsuit against Amgen in the Delaware District Court alleging infringement of 14 patents. All but 2 of the 14 patents asserted in this lawsuit have already been the subject of litigation pending among these parties in this court relating to Amgen’s submission of the application that led to the FDA licensure of MVASI TM as biosimilar to Genentech’s Avastin ® (bevacizumab). Among other remedies, Genentech and City of Hope are seeking injunctive relief. Humira ® Biosimilar Antitrust Class Actions From March 18, 2019, to April 19, 2019, ten purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie), were filed in the U.S. District Court for the Northern District of Illinois. The cases are captioned: UFCW Local 1500 Welfare Fund v. AbbVie Inc., et al. (March 18, 2019) (Local 1500); Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund v. AbbVie Inc., et al. (March 20, 2019); Mayor and City Council of Baltimore v. AbbVie Inc., et al. (March 22, 2019); Pipe Trades Services MN Welfare Fund v. AbbVie Inc., et al. (March 29, 2019); St. Paul Electrical Workers’ Health Plan v. AbbVie Inc., et al. (March 29, 2019); Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C, and 137R v. AbbVie Inc., et al. (April 1, 2019); Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. (April 9, 2019) (Law Enforcement); Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. (April 16, 2019); Sheet Metal Workers’ Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al. (April 19, 2019) (Sheet Metal Workers’); and Locals 302 & 612 of The International Union of Operating Engineers-Employers Construction Industry Health And Security Trust Fund v. AbbVie Inc., et al. (April 25, 2019) (Construction Industry) (collectively, Humira ® Antitrust Class Actions). In each of the Humira ® Antitrust Class Actions, the plaintiffs bring federal antitrust claims along with various state law claims under state common law and state antitrust, consumer protection, and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully monopolized the alleged market for Humira ® and biosimilars of Humira ® , including by creating an allegedly unlawful so-called patent thicket around Humira ® . In the Local 1500, Sheet Metal Workers’ and Construction Industry cases, the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira ® biosimilars, including Samsung Bioepis Co., Ltd., Mylan Inc., Mylan Pharmaceuticals, Inc., Sandoz, Inc., Fresenius Kabi USA, LLC, Pfizer Inc. and Momenta Pharmaceuticals, Inc., in connection with the settlement of patent litigation relating to Humira ® , whereby Amgen and the other defendants that have developed Humira ® biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira ® Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA TM , its Humira ® biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira ® biosimilar in that market for five months, beginning in January 2023. In each of the Humira ® Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney’s fees on behalf of a putative class of third-party payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira ® in the United States. Defendants’ responses to the first six complaints were stayed by the court and a status hearing is set for May 2, 2019. U.S. Attorney’s Office for the District of Massachusetts - Patient Assistance Investigation On April 25, 2019, Amgen, the U.S. Department of Justice and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services entered into a settlement agreement. Under that agreement, Amgen agreed to pay $24.75 million to resolve the government’s allegations relating to Amgen’s support of independent charitable organizations that provide patients with financial assistance to access their medicines. Additionally, Amgen and OIG entered into a Corporate Integrity Agreement that requires Amgen to maintain its corporate compliance program and to undertake a set of defined corporate integrity obligations for a period of five years .

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation	Basis of presentation The financial information for the three months ended March 31, 2019 and 2018 , is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2018
Principles of consolidation	Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $7.9 billion and $7.8 billion as of March 31, 2019 and December 31, 2018 , respectively.
Leases	Leases Adoption of new lease standard In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method. This approach provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is related primarily to previously existing lease liabilities. The standard did not materially impact our Condensed Consolidated Statements of Income and had no impact on our Condensed Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 8, Leases. Lease recognition At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Condensed Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.
Other recent accounting pronouncements	Other recent accounting pronouncements In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.

Revenues (Tables)

Revenues (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue by product and by geographic area	Revenues were as follows (in millions): Three months ended March 31, 2019 2018 US ROW Total US ROW Total Enbrel ® (etanercept) $ 1,106 $ 45 $ 1,151 $ 1,050 $ 55 $ 1,105 Neulasta ® (pegfilgrastim) 893 128 1,021 1,009 146 1,155 Prolia ® (denosumab) 390 202 592 320 174 494 XGEVA ® (denosumab) 356 115 471 332 113 445 Aranesp ® (darbepoetin alfa) 182 232 414 225 229 454 KYPROLIS ® (carfilzomib) 154 91 245 137 85 222 EPOGEN ® (epoetin alfa) 219 — 219 244 — 244 Sensipar ® /Mimpara ® (cinacalcet) 135 78 213 409 88 497 Other products 556 404 960 421 306 727 Total product sales (1) $ 3,991 $ 1,295 5,286 $ 4,147 $ 1,196 5,343 Other revenues 271 211 Total revenues $ 5,557 $ 5,554 ____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2019 and 2018 .

Earnings per share (Tables)

Earnings per share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Computation for basic and diluted earnings per share	The computations for basic and diluted EPS were as follows (in millions, except per-share data): Three months ended 2019 2018 Income (Numerator): Net income for basic and diluted EPS $ 1,992 $ 2,311 Shares (Denominator): Weighted-average shares for basic EPS 622 707 Effect of dilutive securities 4 4 Weighted-average shares for diluted EPS 626 711 Basic EPS $ 3.20 $ 3.27 Diluted EPS $ 3.18 $ 3.25

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of March 31, 2019 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,709 $ — $ (27 ) $ 2,682 U.S. Treasury bills 3,475 — — 3,475 Other government-related debt securities: U.S. 112 — (1 ) 111 Foreign and other 964 4 (10 ) 958 Corporate debt securities: Financial 2,771 1 (22 ) 2,750 Industrial 2,481 4 (27 ) 2,458 Other 572 1 (7 ) 566 Residential-mortgage-backed securities 1,404 — (22 ) 1,382 Other mortgage- and asset-backed securities 478 — (11 ) 467 Money market mutual funds 4,375 — — 4,375 Other short-term interest-bearing securities 6,428 — — 6,428 Total interest-bearing securities $ 25,769 $ 10 $ (127 ) $ 25,652 Types of securities as of December 31, 2018 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,710 $ — $ (47 ) $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. 112 — (2 ) 110 Foreign and other 972 1 (41 ) 932 Corporate debt securities: Financial 2,778 — (81 ) 2,697 Industrial 2,603 — (99 ) 2,504 Other 583 — (21 ) 562 Residential-mortgage-backed securities 1,458 — (36 ) 1,422 Other mortgage- and asset-backed securities 483 — (14 ) 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities 3,515 — — 3,515 Total interest-bearing securities $ 29,064 $ 1 $ (341 ) $ 28,724
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): Condensed Consolidated Balance Sheets locations March 31, December 31, Cash and cash equivalents $ 6,709 $ 6,365 Marketable securities 18,943 22,359 Total interest-bearing securities $ 25,652 $ 28,724
Fair values of available-for-sale interest-bearing security investments by contractual maturity	The fair values of interest-bearing securities by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions): Contractual maturities March 31, December 31, Maturing in one year or less $ 14,357 $ 17,424 Maturing after one year through three years 4,600 3,356 Maturing after three years through five years 3,987 5,168 Maturing after five years through ten years 859 885 Mortgage- and asset-backed securities 1,849 1,891 Total interest-bearing securities $ 25,652 $ 28,724
Available-for-sale securities, continuous unrealized loss position, fair value	The fair values and gross unrealized losses of interest-bearing securities in an unrealized loss position aggregated by type and length of time that the securities have been in a continuous loss position were as follows (in millions): Less than 12 months 12 months or more Types of securities as of March 31, 2019 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,190 $ (11 ) $ 1,452 $ (16 ) Other government-related debt securities: U.S. — — 111 (1 ) Foreign and other 410 (6 ) 307 (4 ) Corporate debt securities: Financial 1,783 (14 ) 822 (8 ) Industrial 1,516 (20 ) 634 (7 ) Other 454 (6 ) 36 (1 ) Residential-mortgage-backed securities 558 (9 ) 809 (13 ) Other mortgage- and asset-backed securities 17 — 450 (11 ) Total $ 5,928 $ (66 ) $ 4,621 $ (61 ) Less than 12 months 12 months or more Types of securities as of December 31, 2018 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,219 $ (21 ) $ 1,444 $ (26 ) Other government-related debt securities: U.S. — — 110 (2 ) Foreign and other 631 (31 ) 240 (10 ) Corporate debt securities: Financial 1,968 (59 ) 718 (22 ) Industrial 1,898 (81 ) 529 (18 ) Other 529 (20 ) 28 (1 ) Residential-mortgage-backed securities 576 (14 ) 840 (22 ) Other mortgage- and asset-backed securities 17 — 451 (14 ) Total $ 6,838 $ (226 ) $ 4,360 $ (115 )

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in millions): March 31, December 31, Raw materials $ 276 $ 257 Work in process 1,770 1,660 Finished goods 970 1,023 Total inventories $ 3,016 $ 2,940

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The change in the carrying amount of goodwill was as follows (in millions): Three months ended Beginning balance $ 14,699 Currency translation adjustment (7 ) Ending balance $ 14,692
Schedule of identifiable intangible assets	Other intangible assets consisted of the following (in millions): March 31, 2019 December 31, 2018 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Finite-lived intangible assets: Developed-product-technology rights $ 12,559 $ (7,639 ) $ 4,920 $ 12,573 $ (7,479 ) $ 5,094 Licensing rights 3,693 (2,064 ) 1,629 3,772 (2,032 ) 1,740 Marketing-related rights 1,211 (947 ) 264 1,297 (1,019 ) 278 Research and development technology rights 1,145 (889 ) 256 1,148 (872 ) 276 Total finite-lived intangible assets 18,608 (11,539 ) 7,069 18,790 (11,402 ) 7,388 Indefinite-lived intangible assets: In-process research and development 55 — 55 55 — 55 Total other intangible assets $ 18,663 $ (11,539 ) $ 7,124 $ 18,845 $ (11,402 ) $ 7,443

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Summary Information, Components of Lease Costs and Cash and Noncash Information on Leases	Cash and noncash information related to our leases was as follows (in millions): Three months ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 34 ROU assets obtained in exchange for lease obligations: Operating leases $ 8 The following table summarizes information related to our leases, which are all classified as operating, included in our Condensed Consolidated Balance Sheets (in millions): Condensed Consolidated Balance Sheets locations March 31, 2019 Assets: Other assets $ 417 Liabilities: Accrued liabilities $ 120 Other noncurrent liabilities 368 Total lease liabilities $ 488 The components of net lease costs were as follows (in millions): Lease costs Three months ended March 31, 2019 Operating (1) $ 48 Sublease income (8 ) Total net lease costs $ 40 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the three months ended March 31, 2019.
Maturities of Lease Liabilities	Maturities of lease liabilities as of March 31, 2019, were as follows (in millions): Maturity dates Operating leases Remaining nine months ending December 31, 2019 $ 135 2020 133 2021 107 2022 63 2023 48 Thereafter 41 Total lease payments (1) 527 Less imputed interest (39 ) Present value of lease liabilities $ 488 ____________ (1) Includes future rental commitments for abandoned leases of $204 million . We expect to receive total future rental income of $166 million related to noncancelable subleases for abandoned facilities.

Financing arrangements (Tables)

Financing arrangements (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Financing arrangements Our borrowings consisted of the following (in millions): March 31, December 31, 5.70% notes due 2019 (5.70% 2019 Notes) $ — $ 1,000 1.90% notes due 2019 (1.90% 2019 Notes) 700 700 Floating Rate Notes due 2019 550 550 2.20% notes due 2019 (2.20% 2019 Notes) 1,400 1,400 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) 757 774 4.50% notes due 2020 (4.50% 2020 Notes) 300 300 2.125% notes due 2020 (2.125% 2020 Notes) 750 750 Floating Rate Notes due 2020 300 300 2.20% notes due 2020 (2.20% 2020 Notes) 700 700 3.45% notes due 2020 (3.45% 2020 Notes) 900 900 4.10% notes due 2021 (4.10% 2021 Notes) 1,000 1,000 1.85% notes due 2021 (1.85% 2021 Notes) 750 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,750 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,402 1,433 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 703 713 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 841 860 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 619 606 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 912 893 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (886 ) (896 ) Fair value adjustments 77 (53 ) Total carrying value of debt 33,024 33,929 Less current portion (3,705 ) (4,419 ) Total long-term debt $ 29,319 $ 29,510 There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6% , respectively.
Schedule of Borrowings	Our borrowings consisted of the following (in millions): March 31, December 31, 5.70% notes due 2019 (5.70% 2019 Notes) $ — $ 1,000 1.90% notes due 2019 (1.90% 2019 Notes) 700 700 Floating Rate Notes due 2019 550 550 2.20% notes due 2019 (2.20% 2019 Notes) 1,400 1,400 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) 757 774 4.50% notes due 2020 (4.50% 2020 Notes) 300 300 2.125% notes due 2020 (2.125% 2020 Notes) 750 750 Floating Rate Notes due 2020 300 300 2.20% notes due 2020 (2.20% 2020 Notes) 700 700 3.45% notes due 2020 (3.45% 2020 Notes) 900 900 4.10% notes due 2021 (4.10% 2021 Notes) 1,000 1,000 1.85% notes due 2021 (1.85% 2021 Notes) 750 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,750 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,402 1,433 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 703 713 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 841 860 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 619 606 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 912 893 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (886 ) (896 ) Fair value adjustments 77 (53 ) Total carrying value of debt 33,024 33,929 Less current portion (3,705 ) (4,419 ) Total long-term debt $ 29,319 $ 29,510

Stockholders' equity (Tables)

Stockholders' equity (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Summary of activity under our stock repurchase program	Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): 2019 2018 Shares Dollars Shares Dollars First quarter 15.9 $ 3,031 56.4 $ 10,787
Components of accumulated other comprehensive income	The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions): Foreign currency translation Cash flow hedges Available-for-sale securities Other AOCI Balance as of December 31, 2018 $ (670 ) $ 241 $ (338 ) $ (2 ) $ (769 ) Foreign currency translation adjustments (13 ) — — — (13 ) Unrealized gains — 30 218 — 248 Reclassification adjustments to income — 28 4 — 32 Income taxes — (13 ) (1 ) — (14 ) Balance as of March 31, 2019 $ (683 ) $ 286 $ (117 ) $ (2 ) $ (516 )
Reclassifications out of accumulated other comprehensive income	Reclassifications out of AOCI and into earnings were as follows (in millions): Three months ended March 31, Components of AOCI 2019 2018 Condensed Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains (losses) $ 14 $ (34 ) Product sales Cross-currency swap contract (losses) gains (42 ) 164 Interest and other income, net (28 ) 130 Income before income taxes 6 (28 ) Provision for income taxes $ (22 ) $ 102 Net income Available-for-sale securities: Net realized losses $ (4 ) $ (134 ) Interest and other income, net — 1 Provision for income taxes $ (4 ) $ (133 ) Net income

Fair value measurement (Tables)

Fair value measurement (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis	The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Quoted prices in Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of March 31, 2019, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 2,682 $ — $ — $ 2,682 U.S. Treasury bills 3,475 — — 3,475 Other government-related debt securities: U.S. — 111 — 111 Foreign and other — 958 — 958 Corporate debt securities: Financial — 2,750 — 2,750 Industrial — 2,458 — 2,458 Other — 566 — 566 Residential-mortgage-backed securities — 1,382 — 1,382 Other mortgage- and asset-backed securities — 467 — 467 Money market mutual funds 4,375 — — 4,375 Other short-term interest-bearing securities — 6,428 — 6,428 Equity securities 246 — — 246 Derivatives: Foreign currency contracts — 238 — 238 Cross-currency swap contracts — 143 — 143 Interest rate swap contracts — 94 — 94 Total assets $ 10,778 $ 15,595 $ — $ 26,373 Liabilities: Derivatives: Foreign currency contracts $ — $ 8 $ — $ 8 Cross-currency swap contracts — 429 — 429 Interest rate swap contracts — 54 — 54 Contingent consideration obligations — — 66 66 Total liabilities $ — $ 491 $ 66 $ 557 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of December 31, 2018, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 2,663 $ — $ — $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. — 110 — 110 Foreign and other — 932 — 932 Corporate debt securities: Financial — 2,697 — 2,697 Industrial — 2,504 — 2,504 Other — 562 — 562 Residential-mortgage-backed securities — 1,422 — 1,422 Other mortgage- and asset-backed securities — 469 — 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities — 3,515 — 3,515 Equity securities 176 — — 176 Derivatives: Foreign currency contracts — 182 — 182 Cross-currency swap contracts — 170 — 170 Interest rate swap contracts — 56 — 56 Total assets $ 16,689 $ 12,619 $ — $ 29,308 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 401 — 401 Interest rate swap contracts — 149 — 149 Contingent consideration obligations — — 72 72 Total liabilities $ — $ 576 $ 72 $ 648

Derivative instruments (Tables)

Derivative instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of notional amounts and interest rates for cross-currency swaps	The notional amounts and interest rates of our cross-currency swaps as of March 31, 2019 , were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 2.125% 2019 euro Notes € 675 2.1 % $ 864 2.6 % 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 %
Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges	The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Derivatives in cash flow hedging relationships 2019 2018 Foreign currency contracts $ 85 $ (89 ) Cross-currency swap contracts (55 ) 238 Total unrealized gains $ 30 $ 149
Location in the Condensed Consolidated Statements of Income and the gain (loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges	The locations in the Condensed Consolidated Statements of Income and the gains and losses reclassified out of AOCI and into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Derivatives in cash flow hedging relationships Condensed Consolidated Statements of Income locations 2019 2018 Foreign currency contracts Product sales $ 14 $ (34 ) Cross-currency swap contracts Interest and other income, net (42 ) 164 Total realized (losses) gains $ (28 ) $ 130
Derivatives in fair value hedging relationships	Net unrealized gains and losses on our outstanding interest rate swap contracts were as follows (in millions): Three months ended Derivatives in fair value hedging relationships 2019 2018 Net unrealized gains (losses) recognized on interest rate swap contracts $ 133 $ (164 ) Net unrealized (losses) gains recognized on related hedged debt $ (133 ) $ 164 The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) Condensed Consolidated Balance Sheets locations March 31, 2019 December 31, 2018 March 31, 2019 December 31, 2018 Current portion of long-term debt $ 1,398 $ 2,396 $ (2 ) $ (3 ) Long-term debt $ 9,494 $ 9,361 $ 79 $ (50 ) ____________ (1) Current portion of long-term debt includes $1.0 billion of carrying value with discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $137 million of carrying value with discontinued hedging relationships as of March 31, 2019 and December 31, 2018 . (2) Current portion of long-term debt includes $3 million of hedging adjustments on discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $37 million of hedging adjustments on discontinued hedging relationships as of March 31, 2019 and December 31, 2018 .
Summary of amounts of income and expense line items	The following table summarizes the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,286 $ 185 $ (343 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 14 $ — $ — Cross-currency swap contracts $ — $ (42 ) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (130 ) Derivatives designated as hedging instruments $ — $ — $ 133 __________ (1) The amounts include benefits of $3 million related to the amortization of the cumulative amount of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships for the three months ended March 31, 2019 .
Fair values of derivatives included in the Condensed Consolidated Balance Sheets	The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities March 31, 2019 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 238 Accrued liabilities/ Other noncurrent liabilities $ 8 Cross-currency swap contracts Other current assets/ Other assets 143 Accrued liabilities/ Other noncurrent liabilities 429 Interest rate swap contracts Other current assets/ Other assets 94 Accrued liabilities/ Other noncurrent liabilities 54 Total derivatives designated as hedging instruments 475 491 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets — Accrued liabilities — Total derivatives not designated as hedging instruments — — Total derivatives $ 475 $ 491 Derivative assets Derivative liabilities December 31, 2018 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 181 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 170 Accrued liabilities/ Other noncurrent liabilities 401 Interest rate swap contracts Other current assets/ Other assets 56 Accrued liabilities/ Other noncurrent liabilities 149 Total derivatives designated as hedging instruments 407 576 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 408 $ 576

Summary of significant accoun_3

Summary of significant accounting policies (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)segment	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Accounting Policies [Abstract]
Number of operating segments | segment	1
Accumulated depreciation and amortization on property, plant and equipment	$ 7,900		$ 7,800
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities	488
ROU asset	$ 417
New Lease Standard
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities		$ 510
ROU asset		$ 439

Revenues (Details)

Revenues (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)segment	Mar. 31, 2018USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments | segment	1
Revenue from External Customer [Line Items]
Total revenues	$ 5,557	$ 5,554
Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales	5,286	5,343
Product sales [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	3,991	4,147
Product sales [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	1,295	1,196
Enbrel® (etanercept) [Member]
Revenue from External Customer [Line Items]
Total product sales	1,151	1,105
Enbrel® (etanercept) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,106	1,050
Enbrel® (etanercept) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	45	55
Neulasta® (pegfilgrastim) [Member]
Revenue from External Customer [Line Items]
Total product sales	1,021	1,155
Neulasta® (pegfilgrastim) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	893	1,009
Neulasta® (pegfilgrastim) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	128	146
Prolia® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	592	494
Prolia® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	390	320
Prolia® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	202	174
XGEVA® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	471	445
XGEVA® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	356	332
XGEVA® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	115	113
Aranesp® (darbepoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales	414	454
Aranesp® (darbepoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	182	225
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	232	229
KYPROLIS® (carfilzomib) [Member]
Revenue from External Customer [Line Items]
Total product sales	245	222
KYPROLIS® (carfilzomib) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	154	137
KYPROLIS® (carfilzomib) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	91	85
EPOGEN® (epoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales	219	244
EPOGEN® (epoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	219	244
EPOGEN® (epoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	0	0
Sensipar® / Mimpara® (cinacalcet) [Member]
Revenue from External Customer [Line Items]
Total product sales	213	497
Sensipar® / Mimpara® (cinacalcet) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	135	409
Sensipar® / Mimpara® (cinacalcet) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	78	88
Other products [Member]
Revenue from External Customer [Line Items]
Total product sales	960	727
Other products [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	556	421
Other products [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	404	306
Other revenues [Member]
Revenue from External Customer [Line Items]
Total revenues	$ 271	$ 211

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Effective income tax rate	13.90%	11.80%
Increase in unrecognized tax benefits resulting from tax positions taken during the current period	$ 90

Earnings per share (Details)

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income (Numerator):
Net income for basic and diluted EPS	$ 1,992	$ 2,311
Shares (Denominator):
Weighted-average shares for basic EPS (in shares)	622	707
Effect of dilutive securities (in shares)	4	4
Weighted-average shares for diluted EPS (in shares)	626	711
Basic EPS (in usd per share)	$ 3.20	$ 3.27
Diluted EPS (in usd per share)	$ 3.18	$ 3.25

Investments (Details)

Investments (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 25,769	$ 29,064
Gross unrealized gains	10	1
Gross unrealized losses	(127)	(341)
Fair values	25,652	28,724
U.S. Treasury notes [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,709	2,710
Gross unrealized gains	0	0
Gross unrealized losses	(27)	(47)
Fair values	2,682	2,663
U.S. Treasury bills [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	3,475	8,191
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	3,475	8,191
Other government-related debt securities - U.S. [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	112	112
Gross unrealized gains	0	0
Gross unrealized losses	(1)	(2)
Fair values	111	110
Other government-related debt securities - Foreign and other [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	964	972
Gross unrealized gains	4	1
Gross unrealized losses	(10)	(41)
Fair values	958	932
Corporate debt securities - Financial [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,771	2,778
Gross unrealized gains	1	0
Gross unrealized losses	(22)	(81)
Fair values	2,750	2,697
Corporate debt securities - Industrial [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,481	2,603
Gross unrealized gains	4	0
Gross unrealized losses	(27)	(99)
Fair values	2,458	2,504
Corporate debt securities - Other [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	572	583
Gross unrealized gains	1	0
Gross unrealized losses	(7)	(21)
Fair values	566	562
Residential mortgage-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	1,404	1,458
Gross unrealized gains	0	0
Gross unrealized losses	(22)	(36)
Fair values	1,382	1,422
Other mortgage- and asset-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	478	483
Gross unrealized gains	0	0
Gross unrealized losses	(11)	(14)
Fair values	467	469
Money market mutual funds [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	4,375	5,659
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	4,375	5,659
Other short-term interest-bearing securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	6,428	3,515
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	$ 6,428	$ 3,515

Investments (Fair Values by Cla

Investments (Fair Values by Classification) (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$ 7,358	$ 6,945	$ 9,741	$ 3,800
Marketable securities	18,943	22,359
Total interest-bearing securities	25,652	28,724
Available-for-sale investments [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	6,709	6,365
Marketable securities	18,943	22,359
Total interest-bearing securities	$ 25,652	$ 28,724

Investments (Available-for-sale

Investments (Available-for-sale Investments) (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Cash and cash equivalents	$ 649		$ 580
Total realized gains	1	$ 17
Total realized losses	$ 5	$ 151

Investments (Fair Values by Con

Investments (Fair Values by Contractual Maturity) (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Maturing in one year or less	$ 14,357	$ 17,424
Maturing after one year through three years	4,600	3,356
Maturing after three years through five years	3,987	5,168
Maturing after five years through ten years	859	885
Mortgage- and asset-backed securities	1,849	1,891
Total interest-bearing securities	$ 25,652	$ 28,724

Investments (Unrealized Losses

Investments (Unrealized Losses and Fair Values) (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	$ 5,928	$ 6,838
Less than 12 months, Unrealized losses	(66)	(226)
12 months or more, Fair values	4,621	4,360
12 months or more, Unrealized losses	(61)	(115)
U.S. Treasury notes [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,190	1,219
Less than 12 months, Unrealized losses	(11)	(21)
12 months or more, Fair values	1,452	1,444
12 months or more, Unrealized losses	(16)	(26)
Other government-related debt securities - U.S. [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	0	0
Less than 12 months, Unrealized losses	0	0
12 months or more, Fair values	111	110
12 months or more, Unrealized losses	(1)	(2)
Other government-related debt securities - Foreign and other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	410	631
Less than 12 months, Unrealized losses	(6)	(31)
12 months or more, Fair values	307	240
12 months or more, Unrealized losses	(4)	(10)
Corporate debt securities - Financial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,783	1,968
Less than 12 months, Unrealized losses	(14)	(59)
12 months or more, Fair values	822	718
12 months or more, Unrealized losses	(8)	(22)
Corporate debt securities - Industrial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,516	1,898
Less than 12 months, Unrealized losses	(20)	(81)
12 months or more, Fair values	634	529
12 months or more, Unrealized losses	(7)	(18)
Corporate debt securities - Other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	454	529
Less than 12 months, Unrealized losses	(6)	(20)
12 months or more, Fair values	36	28
12 months or more, Unrealized losses	(1)	(1)
Residential mortgage-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	558	576
Less than 12 months, Unrealized losses	(9)	(14)
12 months or more, Fair values	809	840
12 months or more, Unrealized losses	(13)	(22)
Other mortgage- and asset-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	17	17
Less than 12 months, Unrealized losses	0	0
12 months or more, Fair values	450	451
12 months or more, Unrealized losses	$ (11)	$ (14)

Investments (Equity Securities)

Investments (Equity Securities) (Details Textual) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Equity securities	$ 246	$ 176
Equity securities without readily determinable fair value	$ 185	$ 222

Investments Investments (Limite

Investments Investments (Limited Partnership Investments) (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Limited Partnership [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Net Investment Income [Line Items]
Investments	$ 275	$ 285

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 276	$ 257
Work in process	1,770	1,660
Finished goods	970	1,023
Total inventories	$ 3,016	$ 2,940

Goodwill and other intangible_3

Goodwill and other intangible assets (Goodwill Roll Forward) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 14,699
Currency translation adjustment	(7)
Ending balance	$ 14,692

Goodwill and other intangible_4

Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	$ 18,608	$ 18,790
Accumulated amortization	(11,539)	(11,402)
Other intangible assets, net	7,069	7,388
Gross carrying amount	18,663	18,845
Accumulated amortization	(11,539)	(11,402)
Intangible assets, net	7,124	7,443
In-process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	55	55
Developed-Product-Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	12,559	12,573
Accumulated amortization	(7,639)	(7,479)
Other intangible assets, net	4,920	5,094
Licensing Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	3,693	3,772
Accumulated amortization	(2,064)	(2,032)
Other intangible assets, net	1,629	1,740
Marketing-Related Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,211	1,297
Accumulated amortization	(947)	(1,019)
Other intangible assets, net	264	278
Research and Development Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,145	1,148
Accumulated amortization	(889)	(872)
Other intangible assets, net	$ 256	$ 276

Goodwill and other intangible_5

Goodwill and other intangible assets (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization charges associated with finite-lived intangible assets	$ 315	$ 320
Total estimated amortization of finite-lived intangible assets for the nine months ending December 31, 2019	1,000
Total estimated amortization of finite-lived intangible assets for 2020	1,200
Total estimated amortization of finite-lived intangible assets for 2021	1,000
Total estimated amortization of finite-lived intangible assets for 2022	900
Total estimated amortization of finite-lived intangible assets for 2023	900
Total estimated amortization of finite-lived intangible assets for 2024	$ 800

Leases (Textual) (Details)

Leases (Textual) (Details)	Mar. 31, 2019
Leases [Abstract]
Renewal term	7 years
Weighted-average remaining lease term (in years)	4 years 6 months
Weighted-average discount rate	3.32%

Leases (Summary of Leases) (Det

Leases (Summary of Leases) (Details) $ in Millions	Mar. 31, 2019USD ($)
Assets:
Other assets	$ 417
Liabilities:
Accrued liabilities	120
Other noncurrent liabilities	368
Total lease liabilities	$ 488

Leases (Components of Lease Cos

Leases (Components of Lease Costs) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating	$ 48
Sublease income	(8)
Total net lease costs	$ 40

Leases (Maturities of Lease Lia

Leases (Maturities of Lease Liabilities) (Details) $ in Millions	Mar. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Remaining nine months ending December 31, 2019	$ 135
2020	133
2021	107
2022	63
2023	48
Thereafter	41
Total lease payments	527
Less imputed interest	(39)
Total lease liabilities	488
Abandoned Leases [Member]
Lessee, Lease, Description [Line Items]
Total lease payments	204
Expected total future rental income to be received	$ 166

Leases (Cash and Noncash Inform

Leases (Cash and Noncash Information of Leases) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 34
ROU assets obtained in exchange for lease obligations	$ 8

Financing arrangements (Princip

Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) $ in Millions	Mar. 31, 2019GBP (£)	Mar. 31, 2019USD ($)	Mar. 31, 2019CHF (SFr)	Mar. 31, 2019EUR (€)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Unamortized bond discounts, premiums and issuance costs, net		$ (886)			$ (896)
Fair value adjustments		(77)			53
Total carrying value of debt		33,024			33,929
Less current portion		(3,705)			(4,419)
Total long-term debt		$ 29,319			29,510
Notes [Member] | 5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross					1,000
Interest rate, stated percentage	5.70%	5.70%	5.70%	5.70%
Notes [Member] | 1.90% notes due 2019 (1.90% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 700			700
Interest rate, stated percentage	1.90%	1.90%	1.90%	1.90%
Notes [Member] | Floating Rate Notes due 2019 [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 550			550
Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,400			1,400
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%
Notes [Member] | 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 757			774
Face amount | €				€ 675,000,000
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 300			300
Interest rate, stated percentage	4.50%	4.50%	4.50%	4.50%
Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 750			750
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Notes [Member] | Floating Rate Notes Due 2020 [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 300			300
Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 700			700
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%
Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 900			900
Interest rate, stated percentage	3.45%	3.45%	3.45%	3.45%
Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,000			1,000
Interest rate, stated percentage	4.10%	4.10%	4.10%	4.10%
Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 750			750
Interest rate, stated percentage	1.85%	1.85%	1.85%	1.85%
Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,750			1,750
Interest rate, stated percentage	3.875%	3.875%	3.875%	3.875%
Notes [Member] | 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,402			1,433
Face amount | €				€ 1,250,000,000
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%
Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 500			500
Interest rate, stated percentage	2.70%	2.70%	2.70%	2.70%
Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,500			1,500
Interest rate, stated percentage	2.65%	2.65%	2.65%	2.65%
Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 750			750
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Notes [Member] | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 703			713
Face amount | SFr			SFr 700,000,000
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 750			750
Interest rate, stated percentage	2.25%	2.25%	2.25%	2.25%
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,400			1,400
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,000			1,000
Interest rate, stated percentage	3.125%	3.125%	3.125%	3.125%
Notes [Member] | 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 841			860
Face amount | €				€ 750,000,000
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,250			1,250
Interest rate, stated percentage	2.60%	2.60%	2.60%	2.60%
Notes [Member] | 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 619			606
Face amount | £	£ 475,000,000
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,000			1,000
Interest rate, stated percentage	3.20%	3.20%	3.20%	3.20%
Notes [Member] | 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 912			893
Face amount | £	£ 700,000,000
Interest rate, stated percentage	4.00%	4.00%	4.00%	4.00%
Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 552			552
Interest rate, stated percentage	6.375%	6.375%	6.375%	6.375%
Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 291			291
Interest rate, stated percentage	6.90%	6.90%	6.90%	6.90%
Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 466			466
Interest rate, stated percentage	6.40%	6.40%	6.40%	6.40%
Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 412			412
Interest rate, stated percentage	5.75%	5.75%	5.75%	5.75%
Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 600			600
Interest rate, stated percentage	4.95%	4.95%	4.95%	4.95%
Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 974			974
Interest rate, stated percentage	5.15%	5.15%	5.15%	5.15%
Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 487			487
Interest rate, stated percentage	5.65%	5.65%	5.65%	5.65%
Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 261			261
Interest rate, stated percentage	5.375%	5.375%	5.375%	5.375%
Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 2,250			2,250
Interest rate, stated percentage	4.40%	4.40%	4.40%	4.40%
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,415			1,415
Interest rate, stated percentage	4.563%	4.563%	4.563%	4.563%
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 3,541			3,541
Interest rate, stated percentage	4.663%	4.663%	4.663%	4.663%
Notes [Member] | Other notes due 2097 [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 100			$ 100

Financing arrangements (Details

Financing arrangements (Details Textual) - Notes [Member]	Mar. 31, 2019
4.563% 2048 Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%
Effective interest rate	6.30%
4.663% 2051 Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%
Effective interest rate	5.60%

Stockholders' equity (Share Rep

Stockholders' equity (Share Repurchase Program) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Equity [Abstract]
Stock repurchased, Shares	15.9	56.4
Stock repurchased	$ 3,031	$ 10,787

Stockholders' equity (Details T

Stockholders' equity (Details Textual) - USD ($) $ / shares in Units, $ in Billions	1 Months Ended		3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Equity [Abstract]
Amount available for stock repurchases under a board approved stock repurchase plan	$ 2.1		$ 2.1
Dividends declared per share (in usd per share)	$ 1.45	$ 1.45	$ 1.45	$ 1.32
Dividends paid per share (in usd per share)	$ 1.45

Stockholders' equity (Component

Stockholders' equity (Components of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	$ 12,500	$ 25,241
Foreign currency translation adjustments	(13)	29
Balance as of end of period	10,832	15,620
Foreign currency translation [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(670)
Foreign currency translation adjustments	(13)
Income taxes	0
Balance as of end of period	(683)
Cash flow hedges [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	241
Unrealized gains	30
Reclassification adjustments to income	28
Income taxes	(13)
Balance as of end of period	286
Available-for-sale securities [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(338)
Unrealized gains	218
Reclassification adjustments to income	4
Income taxes	(1)
Balance as of end of period	(117)
Other [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(2)
Unrealized gains	0
Balance as of end of period	(2)
AOCI [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(769)	(679)
Foreign currency translation adjustments	(13)
Unrealized gains	248
Reclassification adjustments to income	32
Income taxes	(14)
Balance as of end of period	$ (516)	$ (994)

Stockholders' equity (Reclassif

Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	$ 185	$ 231
Income before income taxes	2,314	2,619
Provision for income taxes	(322)	(308)
Net income	1,992	2,311
Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	5,286	5,343
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	(28)	130
Provision for income taxes	6	(28)
Net income	(22)	102
Reclassification out of Accumulated Other Comprehensive Income [Member] | Available-for-sale securities [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	(4)	(134)
Provision for income taxes	0	1
Net income	(4)	(133)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	14
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	(42)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	(28)	130
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	14	(34)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	$ (42)	$ 164

Fair value measurement (Details

Fair value measurement (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Assets:
Interest-bearing securities	$ 25,652	$ 28,724
Equity securities	246	176
Derivatives:
Total assets	26,373	29,308
Derivatives:
Contingent consideration obligations	66	72
Total liabilities	557	648
Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	238	182
Derivatives:
Foreign currency and cross-currency swap contracts	8	26
Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	143	170
Derivatives:
Foreign currency and cross-currency swap contracts	429	401
Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	94	56
Derivatives:
Interest rate swap contracts	54	149
Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Equity securities	246	176
Derivatives:
Total assets	10,778	16,689
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
Significant other observable inputs (Level 2) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	15,595	12,619
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	491	576
Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	238	182
Derivatives:
Foreign currency and cross-currency swap contracts	8	26
Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	143	170
Derivatives:
Foreign currency and cross-currency swap contracts	429	401
Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	94	56
Derivatives:
Interest rate swap contracts	54	149
Significant unobservable inputs (Level 3) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	0	0
Derivatives:
Contingent consideration obligations	66	72
Total liabilities	66	72
Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	2,682	2,663
U.S. Treasury notes [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	2,682	2,663
U.S. Treasury notes [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury notes [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	3,475	8,191
U.S. Treasury bills [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	3,475	8,191
U.S. Treasury bills [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury bills [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	111	110
Other government-related debt securities - U.S. [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - U.S. [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	111	110
Other government-related debt securities - U.S. [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	958	932
Other government-related debt securities - Foreign and other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - Foreign and other [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	958	932
Other government-related debt securities - Foreign and other [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	2,750	2,697
Corporate debt securities - Financial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Financial [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	2,750	2,697
Corporate debt securities - Financial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	2,458	2,504
Corporate debt securities - Industrial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Industrial [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	2,458	2,504
Corporate debt securities - Industrial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	566	562
Corporate debt securities - Other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Other [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	566	562
Corporate debt securities - Other [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	1,382	1,422
Residential mortgage-backed securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Residential mortgage-backed securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	1,382	1,422
Residential mortgage-backed securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	467	469
Other mortgage- and asset-backed securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other mortgage- and asset-backed securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	467	469
Other mortgage- and asset-backed securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Money market mutual funds [Member]
Assets:
Interest-bearing securities	4,375	5,659
Money market mutual funds [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	4,375	5,659
Money market mutual funds [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
Money market mutual funds [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	6,428	3,515
Other short-term interest-bearing securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other short-term interest-bearing securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	6,428	3,515
Other short-term interest-bearing securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	$ 0	$ 0

Fair value measurement (Detai_2

Fair value measurement (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Length of time hedged in foreign currency contracts (or less)	3 years
Long-term debt, fair value	$ 34,800	$ 35,000
Carrying value of debt	$ 33,024	$ 33,929
Other Government-related and Corporate Debt Securities [Member]
Business Acquisition [Line Items]
Investment maturity period	5 years

Derivative instruments (Details

Derivative instruments (Details Textual) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps	$ (83)
Derivatives designated as hedging instrument [Member] | Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	4,500	$ 4,500
Derivatives designated as hedging instrument [Member] | Foreign currency option contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	21	21
Derivatives designated as hedging instrument [Member] | Interest rate swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	10,950	10,950
Derivatives not designated as hedging instrument [Member] | Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	$ 891	$ 737

Derivative instruments (Cross-c

Derivative instruments (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member] € in Millions, £ in Millions, SFr in Millions, $ in Millions	Mar. 31, 2019GBP (£)	Mar. 31, 2019USD ($)	Mar. 31, 2019CHF (SFr)	Mar. 31, 2019EUR (€)
2.125% 2019 euro Notes [Member]
Derivative [Line Items]
Notional amounts		$ 864		€ 675
1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Notional amounts		1,388		1,250
0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Notional amounts		704	SFr 700
2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Notional amounts		833		€ 750
5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	£ 475	747
4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	£ 700	$ 1,111
Euro Member Countries, Euro | 2.125% 2019 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.125%	2.125%	2.125%	2.125%
Euro Member Countries, Euro | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	1.25%	1.25%	1.25%	1.25%
Euro Member Countries, Euro | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.00%	2.00%	2.00%	2.00%
Switzerland, Francs | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	0.41%	0.41%	0.41%	0.41%
United Kingdom, Pounds | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	5.50%	5.50%	5.50%	5.50%
United Kingdom, Pounds | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.00%	4.00%	4.00%	4.00%
United States of America, Dollars | 2.125% 2019 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.60%	2.60%	2.60%	2.60%
United States of America, Dollars | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.20%	3.20%	3.20%	3.20%
United States of America, Dollars | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	3.40%	3.40%	3.40%	3.40%
United States of America, Dollars | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.90%	3.90%	3.90%	3.90%
United States of America, Dollars | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	6.00%	6.00%	6.00%	6.00%
United States of America, Dollars | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.50%	4.50%	4.50%	4.50%

Derivative instruments (Effecti

Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	$ 30	$ 149
Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	85	(89)
Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	$ (55)	$ 238

Derivative instruments (Locatio

Derivative instruments (Locations and Effective Portions of Gain (Loss) Reclassified out of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	$ 185	$ 231
Income before income taxes	2,314	2,619
Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	5,286	5,343
Accumulated net gain (loss) from cash flow hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Income before income taxes	(28)	130
Accumulated net gain (loss) from cash flow hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign currency contracts [Member] | Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	14
Accumulated net gain (loss) from cash flow hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	(42)
Accumulated net gain (loss) from cash flow hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedge [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Income before income taxes	(28)	130
Accumulated net gain (loss) from cash flow hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedge [Member] | Foreign currency contracts [Member] | Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	14	(34)
Accumulated net gain (loss) from cash flow hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedge [Member] | Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	$ (42)	$ 164

Derivative instruments Derivati

Derivative instruments Derivative instruments (Fair Value Hedging Relationships) (Details) - Interest expense, net [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Derivative [Line Items]
Net unrealized gains (losses) recognized on interest rate swap contracts	$ 133	$ (164)
Net unrealized (losses) gains recognized on related hedged debt	$ (133)	$ 164

Derivative instruments (Hedged

Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Derivative [Line Items]
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	$ (77)	$ 53
Current portion of long-term debt [Member]
Derivative [Line Items]
Carrying amounts of hedged liabilities	1,398	2,396
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	(2)	(3)
Carrying value with discontinued hedging relationships		1,000
Hedging adjustments on discontinued hedging relationships		3
Long-term debt [Member]
Derivative [Line Items]
Carrying amounts of hedged liabilities	9,494	9,361
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	79	(50)
Carrying value with discontinued hedging relationships	137	137
Hedging adjustments on discontinued hedging relationships	$ 37	$ 37

Derivative instruments (Summary

Derivative instruments (Summary of Income and Expense Line Items) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	$ 185	$ 231
Interest expense, net	(343)	(338)
Amortization of cumulative amount of fair value hedging adjustments for discontinued hedging relationships	3
Interest rate swap agreements [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) on fair value hedging relationships, Hedged items	(130)
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments	133
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	(42)
Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	5,286	$ 5,343
Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	$ 14

Derivative instruments (Fair Va

Derivative instruments (Fair Value of Derivatives) (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Assets
Total derivative assets, fair value	$ 475	$ 408
Liabilities
Total derivative liabilities, fair value	491	576
Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	475	407
Liabilities
Total derivative liabilities, fair value	491	576
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	238	181
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	8	26
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	143	170
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	429	401
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	94	56
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	54	149
Derivatives not designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	0	1
Liabilities
Total derivative liabilities, fair value	0	0
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets [Member]
Assets
Total derivative assets, fair value	0	1
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities [Member]
Liabilities
Total derivative liabilities, fair value	$ 0	$ 0

Contingencies and commitments (

Contingencies and commitments (Details) $ in Thousands	Apr. 25, 2019USD ($)	Apr. 04, 2019agreement	Apr. 19, 2019complaintslawsuit	Apr. 10, 2019actionsplaintiffslawsuit	Mar. 31, 2019patent
Subsequent Event [Member] | Settlement Agreement with U.S. Department of Justice and Office of Inspector General [Member]
Loss Contingencies [Line Items]
Loss contingency, amount agreed to be paid | $	$ 24,750
Corporate Integrity Agreement with OIG, term	5 years
Sensipar Antitrust Class Actions [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiffs				4
Number of actions brought in Delaware District Court | actions				2
Number of lawsuits | lawsuit				4
MVASI Patent Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed | patent					14
MVASI Patent Litigation [Member] | Seeking Injunctive Relief [Member]
Loss Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed | patent					2
Humira Biosimilar Antitrust Class Actions [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of lawsuits | lawsuit			10
Number of complaints stayed by the court | complaints			6
Novartis Breach of Contract Action [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of collaboration agreements breached | agreement		2

Uncategorized Items - amgn-2019

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 29,000,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 38,000,000